RS62152B1 - Bakterije oslabljene virulencije za lečenje malignih solidnih tumora - Google Patents

Bakterije oslabljene virulencije za lečenje malignih solidnih tumora

Info

Publication number
RS62152B1
RS62152B1 RS20210926A RSP20210926A RS62152B1 RS 62152 B1 RS62152 B1 RS 62152B1 RS 20210926 A RS20210926 A RS 20210926A RS P20210926 A RSP20210926 A RS P20210926A RS 62152 B1 RS62152 B1 RS 62152B1
Authority
RS
Serbia
Prior art keywords
treatment
solid tumors
attenuated bacteria
malignant solid
virulence attenuated
Prior art date
Application number
RS20210926A
Other languages
English (en)
Inventor
Simon Ittig
Marlise Amstutz
Christoph Kasper
Guy R Cornelis
Original Assignee
Univ Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Basel filed Critical Univ Basel
Publication of RS62152B1 publication Critical patent/RS62152B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0275Salmonella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0291Yersinia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/104Pseudomonadales, e.g. Pseudomonas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
RS20210926A 2015-11-19 2016-11-17 Bakterije oslabljene virulencije za lečenje malignih solidnih tumora RS62152B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15195490 2015-11-19
EP16797930.1A EP3377094B1 (en) 2015-11-19 2016-11-17 Virulence attenuated bacteria for treatment of malignant solid tumors
PCT/EP2016/078084 WO2017085233A1 (en) 2015-11-19 2016-11-17 Virulence attenuated bacteria for treatment of malignant solid tumors

Publications (1)

Publication Number Publication Date
RS62152B1 true RS62152B1 (sr) 2021-08-31

Family

ID=54697464

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20210926A RS62152B1 (sr) 2015-11-19 2016-11-17 Bakterije oslabljene virulencije za lečenje malignih solidnih tumora

Country Status (24)

Country Link
US (1) US11166987B2 (sr)
EP (2) EP3903813A1 (sr)
JP (1) JP7060503B2 (sr)
KR (1) KR20180081583A (sr)
CN (1) CN108472348B (sr)
AU (1) AU2016358257B2 (sr)
BR (2) BR122023024697A2 (sr)
CA (1) CA3003563A1 (sr)
CY (1) CY1124564T1 (sr)
DK (1) DK3377094T3 (sr)
EA (1) EA201890868A1 (sr)
ES (1) ES2880431T3 (sr)
HK (1) HK1256137A1 (sr)
HR (1) HRP20211191T1 (sr)
HU (1) HUE055132T2 (sr)
IL (1) IL259052B2 (sr)
LT (1) LT3377094T (sr)
PL (1) PL3377094T3 (sr)
PT (1) PT3377094T (sr)
RS (1) RS62152B1 (sr)
SG (1) SG11201803643TA (sr)
SI (1) SI3377094T1 (sr)
WO (1) WO2017085233A1 (sr)
ZA (1) ZA201803902B (sr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016027196B1 (pt) 2014-05-21 2023-05-02 Universität Basel Vetor e cepa bacteriana gram-negativa recombinante
EA039922B1 (ru) 2015-11-19 2022-03-28 Университет Базель Доставка белка бактериями
US11518789B2 (en) 2016-12-20 2022-12-06 Universitaet Basel Virulence attenuated bacteria based protein delivery
KR102110993B1 (ko) * 2018-12-20 2020-05-14 한국생명공학연구원 클레브시엘라 아에로제네스(Klebsiella aerogenes) 균주를 유효성분으로 포함하는 암 진단, 예방 또는 치료용 조성물
AU2021370840A1 (en) * 2020-10-27 2023-06-22 T3 Pharmaceuticals Ag Bacteria based protein delivery
CN114712496B (zh) * 2022-04-29 2023-10-13 中山大学·深圳 一种展示新抗原的细菌衍生外膜囊泡疫苗及制备方法和在制备癌症免疫治疗试剂盒中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965381A (en) * 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
US6596509B1 (en) 1998-07-10 2003-07-22 Cornell Research Foundation, Inc. Recombinant constructs and systems for secretion of proteins via type III secretion systems
US20020160502A1 (en) 2000-09-26 2002-10-31 Roger Williams Hospital Recombinant BCG vaccines for the prevention and treatment of cancer
AU2002312778A1 (en) 2001-03-26 2002-10-08 Universite Catholique De Louvain Type iii bacterial strains for use in medicine
WO2004041151A2 (en) * 2002-11-07 2004-05-21 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
FR2862312B1 (fr) 2003-11-13 2006-02-17 Univ Grenoble 1 Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas
WO2007044406A2 (en) 2005-10-04 2007-04-19 Ludwig Institute For Cancer Research Methods for stimulating an immune response using bacterial antigen delivery system
WO2008019183A2 (en) 2006-05-18 2008-02-14 The Regents Of The University Of California Biopolymer and protein production using type iii secretion systems of gram negative bacteria
TW200819540A (en) * 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
JP5670875B2 (ja) 2008-03-17 2015-02-18 ウニベルジテーツクリニクム ミュンスター カーゴ分子の送達ビヒクルおよび炎症反応を免疫調節するための生物学的治療剤としてのYopM
AU2012267176B2 (en) * 2011-06-08 2017-06-15 Chelation Partners Incorporated Metal chelating compositions and methods for controlling the growth or activities of a living cell or organism
US9127284B2 (en) * 2012-05-04 2015-09-08 The University Of Hong Kong Modified bacteria and their uses thereof for the treatment of cancer or tumor
EP3049526B1 (en) 2013-09-24 2021-02-24 Medicenna Therapeutics, Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
US10143743B2 (en) 2013-11-18 2018-12-04 Yale University Non-replicating bacterial nanoparticle delivery system and methods of use
BR112016027196B1 (pt) 2014-05-21 2023-05-02 Universität Basel Vetor e cepa bacteriana gram-negativa recombinante
EA039922B1 (ru) 2015-11-19 2022-03-28 Университет Базель Доставка белка бактериями
US11518789B2 (en) 2016-12-20 2022-12-06 Universitaet Basel Virulence attenuated bacteria based protein delivery

Also Published As

Publication number Publication date
AU2016358257A1 (en) 2018-05-10
JP7060503B2 (ja) 2022-04-26
JP2019500026A (ja) 2019-01-10
PT3377094T (pt) 2021-07-08
US20190015497A1 (en) 2019-01-17
DK3377094T3 (da) 2021-08-02
WO2017085233A1 (en) 2017-05-26
BR112018009753A8 (pt) 2019-02-26
US11166987B2 (en) 2021-11-09
KR20180081583A (ko) 2018-07-16
ZA201803902B (en) 2019-03-27
HRP20211191T1 (hr) 2021-10-29
CY1124564T1 (el) 2022-07-22
SI3377094T1 (sl) 2021-09-30
CA3003563A1 (en) 2017-05-26
EA201890868A1 (ru) 2018-12-28
SG11201803643TA (en) 2018-06-28
PL3377094T3 (pl) 2021-12-13
CN108472348B (zh) 2022-12-27
IL259052B2 (en) 2024-03-01
EP3377094A1 (en) 2018-09-26
EP3377094B1 (en) 2021-04-28
IL259052B1 (en) 2023-11-01
HK1256137A1 (zh) 2019-09-13
AU2016358257B2 (en) 2023-08-17
IL259052A (en) 2018-07-31
EP3903813A1 (en) 2021-11-03
CN108472348A (zh) 2018-08-31
BR112018009753B1 (pt) 2024-02-20
HUE055132T2 (hu) 2021-11-29
BR112018009753A2 (pt) 2018-11-13
LT3377094T (lt) 2021-08-10
ES2880431T3 (es) 2021-11-24
BR122023024697A2 (pt) 2023-12-26

Similar Documents

Publication Publication Date Title
HK1247202A1 (zh) 用於治療癌症的化合物
ZA201703585B (en) Combination immunotherapy approach for treatment of cancer
HRP20190580T1 (hr) Kombinirana terapija radi liječenja rezistentnih bakterijskih infekcija
HK1256137A1 (zh) 用於治療惡性實體腫瘤的減毒細菌
IL285077A (en) Compounds for the treatment of cancer
HUE053654T2 (hu) FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
IL259996A (en) Combinations for cancer treatment
SG11201607130RA (en) Combination method for treatment of cancer
HK1247931A1 (zh) 用於診斷和治療癌症的組合物和方法
EP3134436A4 (en) Treatment of h-ras-driven tumors
HK1251009B (zh) 用於治療癌症的治療組合物
HK1250949A1 (zh) 使用由減毒細菌遞送的回憶抗原治療癌症
IL263697A (en) Compounds, preparations and methods for the treatment and/or prevention of cancer
GB201408297D0 (en) Treatment of cancer
ZA201707024B (en) Cancer treatment composition
IL255167A0 (en) Compounds for the treatment of cancer
EP3389670A4 (en) METHODS OF TREATING BREAST CANCER
GB201417456D0 (en) Treatment of cancer
HK1259029A1 (zh) 用於治療癌症的具有抗趨除特性的組合物
ZA201704589B (en) Compounds for the treatment of cancer
GB201512723D0 (en) Treatment of cancer
GB201507928D0 (en) Treatment of cancer
GB201504617D0 (en) Treatment of cancer
EP3125878A4 (en) Methods of treating breast cancer
GB201409362D0 (en) Treatment of cancer